The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis

One-third of pneumococcal meningitis (PM) survivors suffer from neurological sequelae including learning disabilities and hearing loss due to excessive neuroinflammation. There is a lack of efficacious compounds for adjuvant therapy to control this long-term consequence of PM. One hallmark is the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Ngoc Dung, Steinfort, Marel, Grandgirard, Denis, Maleska, Aleksandra, Leppert, David, Kuhle, Jens, Leib, Stephen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334283/
https://www.ncbi.nlm.nih.gov/pubmed/35902720
http://dx.doi.org/10.1038/s41598-022-17282-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334283/
https://www.ncbi.nlm.nih.gov/pubmed/35902720
http://dx.doi.org/10.1038/s41598-022-17282-0

Ejemplares similares